FASN and Hyperglycemia: REV-ERB agonists could effectively inhibit the expressions of fatty acid synthase (FASN), stearoyl-CoA desaturase 1 (SCD1), and PPAR-γ coactivator 1 β (PGC-1 β) in diet-induced obese mice, in addition to decreasing fat mass, improving dyslipidemia and hyperglycemia, and reducing obesity.